- Stocks May Rise Further after Fed Waves on 'Risk Trade'
- Obama in China Grapples with Economic Strains
- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Microsoft Co-founder Allen Diagnosed with Cancer
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- What's Kept Stock Rally Going? Fear, Not Confidence
- US Cities With Most Underwater Mortgages
- Citi Shares, A Strange Indicator Of Unemployment?
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- U.S. May Wind Up Green With Envy
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Solar Emerges From A Dark Period
- Fed Likely to Keep Rates Low Despite Dollar's Fall: Bernanke
- Oil Tomorrow
- Gold Is in a 'Bubble' And Will Keep Going Higher: Gartman
Text Size 
Amgen reported a profit and sales that climbed higher and beat analysts' forecasts as sales of some key drugs topped expectations.
 |
The biotechnology company also raised its earnings forecast for the full year.
Amgen said it earned $1.14 a share on a topline of $3.76 billion excluding one-time items, against a profit of $1.12 a share on sales of $3.73 billion in the same period last year.
A consensus estimate put the biotechnology giant's performance at $1.02 a share on sales of $3.583 billion.
Amgen boosted its 2008 adjusted earnings forecast from a prior range of $4.00 to $4.30 a share to a new range of $4.25 to $4.45 a share. The company now expects 2008 revenue of $14.6 billion to $14.9 billion, up from $14.2 billion to $14.6 billion.
Amgen said its second-quarter net profit including one-time charges and other items fell to $941 million, or 87 cents per share, from $1.02 billion, or 90 cents per share, a year ago.
Shares of Amgen were more than 2 percent higher in extended electronic trading.
The erosion of the anemia franchise slowed in the quarter as worldwide sales of red blood cell booster Aranesp—long considered Amgen's most important product—fell 13 percent from a year ago to $825 million. But that was an increase over the previous quarter and crushed Wall Street's diminished expectations of $727 million.
Sales of the older Epogen, which is used primarily in kidney dialysis patients and has been hit with similar safety concerns, fell only slightly to $622 million from $624 million and also topped expectations of $583 million.
Sales of Enbrel, a treatment for rheumatoid arthritis and the skin condition psoriasis, rose just 2 percent to $841 million, shy of analyst estimates of $855 million.
Combined global sales of Neulasta and Neupogen, used to boost white blood cells, rose 15 percent to $1.20 billion, edging past Wall Street estimates of $1.13 billion. (See the accompanying video for more details.)
Amgen stock [AMGN
Loading...
()
] jumped more than 12 percent during regular market hours, largely because of the company's late Friday announcement that a trial of its experimental osteoporosis drug denosumab met its goal of reducing the risk of bone fracture in post-menopausal women.
Amgen shares, under assault for most of 2007, have been recovering, rising some 30 percent this year as positive denosumab data has drowned out the steady drum beat of bad news involving its once top-selling anemia drugs.
- Wire services contributed to this report.
Print
Email
- Where, what, how.
- CNBC's Jim Goldman asks: Has the sun begun to set on Twitter? Data suggests its best days are over.
- Everyone wanted a piece of Madoff's "Bullship"--the famous buoy sold for $7,500 at auction. You won't believe these prices.
- De Loach Vineyards is selling its pinot noir the old fashioned way, helping to cut energy and transportation costs.
- Why are the Chinese concerned about the progress of U.S. health care legislation?
- CNBC's Maria Bartiromo talks to rapper Snoop Dogg about brand identity in both business and music.
Data is a real-time snapshot *Data is delayed at least 15 minutes